Tucatinib 150 mg Tablet

Tucatinib 150 mg Tablet — Patient Access Information (Named Patient Supply)

Tucatinib 150 mg Tablets is an orally administered tyrosine kinase inhibitor (TKI) that is used in the treatment of breast cancer. Such a therapy is directed at the human epidermal growth factor receptor 2 (HER2) pathway, which serves to delay tumor progression in patients with an advanced or metastatic disease. The usage of tucatinib 150 mg tablets is to be done under strict medical supervision, and the supply is to be limited to named patient or case-specific programs.

Tucatinib Uses / Indications

Tucatinib Uses in the treatment of:

• Metastatic breast cancer of HER2.
• Patients whose central nervous system is involved as ruled out by a specialist.
• The treatment may be given instead or together with other accepted chemotherapeutic agents or targeted agents to HER 2 according to the progression and clinical preference of the disease.
• The decision to use Tucatinib 150 mg is made by an oncologist after careful analysis of the history of the patient and tumor profile.

Mechanism of Action

• The selective inhibitor of HER2 tyrosine kinase receptor is tucatinib 150 mg.
• It inhibits this pathway by preventing proliferation cues in cancer cells expressing HER2 but not normal human receptors of the HER family, this is minimizing off-task mitigation.
• Tucatinib tablets in combination with other therapies promote better tumor control and patient outcomes.

Key Benefits

• Selective destruction of tumor cells with the HER2 positive phenotype.
• Capability of passing through the central nervous system, treating brain metastases.
• Minimized off-target toxicity because of selective inhibition of HER2.
• Treatable with conventional HER2-directed interventions.
• This favors the further therapy provided with close medical supervision.

Possible Side Effects

Like all treatments of oncology, there can be adverse effects.

Common side effects include:

• Diarrhea
• Fatigue
• Nausea
• Elevated liver enzymes

Side effects are more severe but less frequent; they include:

• Hepatotoxicity
• Intensive diarrhea or dehydration
• Cardiac dysfunction
• Pulmonary complications
• Close observation of the patients should be conducted and any undesirable events reported to the supervising healthcare professional in time.

Prescription & Supervision Statement

• This drug is prescription-only, and must not be used without the guidance of an experienced oncologist or other medical worker with experience in dealing with HER2-positive breast cancer.

Named Patient Supply Information

• Oddway International offers tucatinib tablets solely within named patient framing schemes or case-particular schemes as required by international regulatory standards provide quality medication in major markets in the USA, UK, Italy, Germany, and Canada.
  
• The appropriate clinical control and regulatory measures are provided as each request is evaluated separately.

Patient Access Disclaimer

• Tucatinib 150 mg is sold under named patient programs, and all decisions concerning the appropriateness of therapy, dosage, and patient monitoring are made by the prescribing clinician.

Why Patients and Healthcare Providers Trust Oddway International

• The specialization of Oddway International is the ethical distribution of prescription medicines through regulated, case-based systems as specialty drug distributors.
• Continuous care is provided to patients who have to obtain special oncological treatment.
• The work of licensed healthcare providers is ensured by the company along with compliance with the legislation and a personalized approach to coordination.